TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03489733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Formula
Description: Infant formula with extensively hydrolyzed proteins and pre- and probiotics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control formula
Description: Infant formula with intact proteins and pre- and probiotics.
Study: NCT01928628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine10mg /Valsartan 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10mg /Valsartan 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipin 10mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipin 10mg Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine10mg /Valsartan 80mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine10mg /Valsartan 80mg Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine 10mg /Valsartan 160mg Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10mg /Valsartan 160mg Placebo
Study: NCT00254566

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: 1 capsule once daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 X 400mg capsule once daily for 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azithromycin SR Placebo
Description: single dose, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin SR
Description: single dose 2.0 g oral
Study: NCT03913663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vestibuloocular training
Description: using vestibulo ocular training program for training neglect patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular exercise training for hemiplegic patients
Description: Traditional gait training program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular exercise training for hemiplegic patients
Description: Traditional gait training program.
Study: NCT02308644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal bevacizumab injection(1.25mg)
Description: intravitreal bevacizumab injection(1.25mg) / Sham injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: intravitreal bevacizumab injection(1.25mg)
Description: intravitreal bevacizumab injection(1.25mg) / Sham injection
Study: NCT03737656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring
Description: Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring
Description: Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring
Description: Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
Study: NCT02144779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned to palliative care team
Description: Communication and Support through the palliative care team assigned to intervention participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: usual hospital care, not assigned to palliative care team
Study: NCT03052647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermaclip
Description: Dermaclip is an adhesive latch device used for skin closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular suture
Description: subcuticular suture will be used as the device to close the skin in this arm
Study: NCT01279057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
Description: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray
Description: Nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Study: NCT01695421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medium-frequency alternating current
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst-modulated alternating current
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
Study: NCT02738671

Intervention type: OTHER
Intervention: olfactory function measurement

Intervention type: OTHER
Intervention: olfactory function measurement
Study: NCT01695421

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
Study: NCT01354132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: n-acetylcysteine
Description: 900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
Study: NCT04186182

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CICI - Feasibility trial study group
Description: The intervention will include 7 individualized meetings with the family (2 home visits + 5 videoconferences), 2 parent group sessions and 4 meetings with school and local care providers, delivered over a 4-5 month period.
Study: NCT02967107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold snare polypectomy
Description: Use of a polypectomy snare closed over a polyp without electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection
Description: Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
Study: NCT02809469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban dose reduction
Description: Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
Study: NCT03452501

Intervention type: DRUG
Intervention: Infliximab
Description: A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

Intervention type: DRUG
Intervention: Infliximab
Description: A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
Study: NCT01270503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT01565343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: IV injection, 370MBq (10mCi)
Study: NCT04163289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
Study: NCT01354132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets are placed in water or juice in the AM and PM
Study: NCT01068444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 1. Name: GLITOS（Pioglitazone）~2. Dosage form: Tablets~3. Dose(s): 30mg~4. Dosing schedule: QD~5. Duration: 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 30 mg/d for 6 months
Study: NCT01270503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT02313740

Intervention type: BIOLOGICAL
Intervention: Butantan Fragmented Inactivated Trivalent Influenza Vaccine
Description: Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).

Intervention type: BIOLOGICAL
Intervention: Butantan Fragmented Inactivated Trivalent Influenza Vaccine
Description: Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
Study: NCT01774214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-Pull technique
Description: Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-Pull technique
Description: Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model.
Study: NCT00253708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Study: NCT01774214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disconnect-Reconnect Technique
Description: Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disconnect-Reconnect Technique
Description: Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles.
Study: NCT01284790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implants
Study: NCT02902094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloons

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non drug eluting balloons
Study: NCT00253708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage therapy
Study: NCT02480530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Feedback
Description: Patient gets feedback reports on adherence weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Feedback
Description: Patient gets feedback reports on adherence weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback Friend
Description: In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
Study: NCT03850821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Social Mechanisms Intervention
Description: The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day.
Study: NCT02972827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM/FloTrac
Description: Use of noninvasive cardiac output and minimally invasive cardiac output monitors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crystalloid Fluid Challenge
Description: 500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
Study: NCT02658448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
Study: NCT03177161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 Patient Reported Health Status Questions
Description: The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 Patient Reported Health Status Questions
Description: The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 Patient Reported Health Status Questions
Description: The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15 Patient Reported Health Status Questions
Description: The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
Study: NCT01901835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mind-body intervention procedure
Description: Participate in media diversion with humorous and non-humorous movies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mind-body intervention procedure
Description: Participate in media diversion with humorous and non-humorous movies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01451801

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Twinrix
Description: A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.~Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin.
Study: NCT02615457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule was given orally, 20 g tid for 5 years.